RA Capital, a multi-stage investment manager, led a $150m Series B round in Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines, with participation from Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures, Mirae Asset Financial, Driehaus Capital Management, Woodline Partners and Soleus Capital. “We are grateful for the support and enthusiasm from such a prestigious group of investors, which reflects the progress of our GPCR Native Complex™ Platform in delivering a pipeline of first-in-class small molecule programs for well-validated but difficult-to-drug GPCR targets. This milestone marks an important transition for Septerna to a product-development company, with plans to advance our lead PTH1R program to clinical proof-of-mechanism, while building out a multi-product pipeline for a range of diseases. This is an exciting time for GPCR drug development, and we are eager to move our novel products toward clinical development. We have established an incredible team that continues to execute and believe Jake’s deep industry insights will be a valuable addition to our board as we continue our work to deliver medicines that improve the lives of patients,” Jeffrey Finer, Septerna CEO and Co-Founder.